8 Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries.

9 Role of Big Data in Cardiovascular Research.

10 Enhancing cardiovascular artificial intelligence (AI) research in the Netherlands: CVON-AI consortium.

11 Morning plasma cortisol as a cardiovascular risk factor: findings from prospective cohort and Mendelian randomization studies.

12 The Simplicity of Modern Audiovisual Web Cartography: An Example with the Open-Source JavaScript Library leaflet.js

13 A Mediterranean Diet Rich in Extra-Virgin Olive Oil Is Associated with a Reduced Prevalence of Nonalcoholic Fatty Liver Disease in Older Individuals at High Cardiovascular Risk.

14 Cardiotrophin-1: A new predictor of atrial fibrillation relapses after successful cardioversion.

15 Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

16 Cardiovascular disease in the literature: A selection of recent original research papers

17 Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes.

18 Use of pulsed electron avalanche knife (PEAK) PlasmaBlade™ in patients undergoing implantation of subcutaneous implantable cardioverter-defibrillator.

19 Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation – a meta-analysis of more than 17000 patients

20 Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation: a Systematic Review and Meta-analysis

21 Vitamin K status and cardiovascular events or mortality: A meta-analysis

22 Comment on “Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis”

23 Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis.

24 A case of Brucella melitensis endocarditis in a patient with cardiovascular implantable electronic device

25 In situ detection of Chlamydia pneumoniae, C. trachomatis, and cytokines among cardiovascular diseased patients from the Amazon region of Brazil

26 Current insights of inspiratory muscle training on the cardiovascular system: a systematic review with meta-analysis

27 Masked hypertension and cardiovascular outcomes: an updated systematic review and meta-analysis

28 Preeclampsia and cardiovascular disease: interconnected paths that enable detection of the subclinical stages of obstetric and cardiovascular diseases

29 Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial

30 The effect of aged garlic extract on blood pressure and other cardiovascular risk factors in uncontrolled hypertensives: the AGE at Heart trial

31 Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine

32 Combining antihypertensive and antihyperlipidemic agents – optimizing cardiovascular risk factor management

33 Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes

34 Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction

35 Can nocturnal hypertension predict cardiovascular risk?

36 Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study

37 Cardiovascular prognosis in patients with preserved left ventricular ejection fraction and no significant ischemia

38 Left atrial appendage closure devices for cardiovascular risk reduction in atrial fibrillation patients

39 Implantable cardioverter defibrillators: state of the art

40 Role of vitamins in cardiovascular health and disease

41 Cardiovascular risk prediction: the old has given way to the new but at what risk-benefit ratio?

42 Clinical utility of ivabradine in cardiovascular disease management: current status

43 Impact of rivaroxaban on stent thrombosis and secondary prevention of cardiovascular events in acute coronary syndrome

44 Cardiovascular protection in type 2 diabetes: time to ADVANCE management ACCORDing to the evidence

45 Clinical utility of low-density lipoprotein particle measurement in management of cardiovascular disease: a case report

46 Cardiovascular disease among patients attending a specialist diabetes clinic in Jamaica

47 High-density lipoproteins: a novel therapeutic target for cardiovascular disease

48 A Cox-Based Risk Prediction Model for Early Detection of Cardiovascular Disease: Identification of Key Risk Factors for the Development of a 10-Year CVD Risk Prediction

49 Pros and Cons of Aspirin Prophylaxis for Prevention of Cardiovascular Events in Kidney Transplantation and Review of Evidence

50 Concordance between the Different Cardiovascular Risk Scores in People with Rheumatoid Arthritis and Psoriasis Arthritis

51 Postoperative ‘STEMI’ in Intracerebral Hemorrhage due to Arteriovenous Malformation: A Case Report and Review of Literature

52 A case of Brucella melitensis endocarditis in a patient with cardiovascular implantable electronic device

53 In situ detection of Chlamydia pneumoniae, C. trachomatis, and cytokines among cardiovascular diseased patients from the Amazon region of Brazil

54 Current insights of inspiratory muscle training on the cardiovascular system: a systematic review with meta-analysis

55 Masked hypertension and cardiovascular outcomes: an updated systematic review and meta-analysis

56 Preeclampsia and cardiovascular disease: interconnected paths that enable detection of the subclinical stages of obstetric and cardiovascular diseases

57 Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial

58 The effect of aged garlic extract on blood pressure and other cardiovascular risk factors in uncontrolled hypertensives: the AGE at Heart trial

59 Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine

60 Combining antihypertensive and antihyperlipidemic agents – optimizing cardiovascular risk factor management

61 Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes

62 Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction

63 Can nocturnal hypertension predict cardiovascular risk?

64 Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study

65 Cardiovascular prognosis in patients with preserved left ventricular ejection fraction and no significant ischemia

66 Left atrial appendage closure devices for cardiovascular risk reduction in atrial fibrillation patients

67 Implantable cardioverter defibrillators: state of the art

68 Role of vitamins in cardiovascular health and disease

69 Cardiovascular risk prediction: the old has given way to the new but at what risk-benefit ratio?

70 Clinical utility of ivabradine in cardiovascular disease management: current status

71 Impact of rivaroxaban on stent thrombosis and secondary prevention of cardiovascular events in acute coronary syndrome

72 Cardiovascular protection in type 2 diabetes: time to ADVANCE management ACCORDing to the evidence

73 Clinical utility of low-density lipoprotein particle measurement in management of cardiovascular disease: a case report

74 Cardiovascular disease among patients attending a specialist diabetes clinic in Jamaica

75 High-density lipoproteins: a novel therapeutic target for cardiovascular disease

76 Leukodepleted Packed Red Blood Cells Transfusion in Patients Undergoing Major Cardiovascular Surgical Procedure: Systematic Review and Meta-Analysis

77 Determinants of increased central excess pressure in dialysis: role of dialysis modality and arteriovenous fistula.

78 Music therapy-induced changes in salivary cortisol level are predictive of cardiovascular mortality in patients under maintenance hemodialysis

79 Promoting cardiovascular health and wellness among African-Americans: Community participatory approach to design an innovative mobile-health intervention.

80 Ethnic disparities in prevalence and clustering of cardiovascular disease risk factors in rural Southwest China.

81 Uterine Fibroids, Race, Ethnicity, and Cardiovascular Outcomes

82 Almanac 2012: Cardiovascular risk scores. The national society journals present selected research that has driven recent advances in clinical cardiology

83 Cardiovascular Risk Assessment in Pilots.

84 Oxidative Balance and Inflammation in Hemodialysis Patients: Biomarkers of Cardiovascular Risk?

85 Blood pressure distribution and control in coronary patients from 24 European countries in the European Society of Cardiology EURoObservational Research Programme European survey of cardiovascular disease prevention and diabetes. EUROASPIRE IV Registry.

86 Assessment of potential cardiovascular risk in trichloroethylene exposure by serum methylated arginine levels.

87 YKL-40 - an emerging biomarker in cardiovascular disease and diabetes

88 Pregnancy-related events associated with subclinical cardiovascular disease burden in late midlife: SWAN.

89 Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study.

90 Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials

91 Brachial-ankle pulse wave velocity predicts all-cause mortality and cardiovascular events in patients with diabetes: The Kyushu prevention study of atherosclerosis

92 Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: A 23-year follow-up study

93 Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: The fremantle diabetes study

94 Update on the use of Trandolapril in the management of cardiovascular disorders

95 Isolation of an ES-Derived Cardiovascular Multipotent Cell Population Based on VE-Cadherin Promoter Activity

96 Did Giovanni dalle Bande Nere become a legendary condottiero because of his MAOA gene?

97 Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study.

98 Does audiovisual information affect anxiety and perceived pain levels in miniscrew application? — a within-person randomized controlled trial

99 Implantable Cardioverter Defibrillator Shocks and Psychological Distress: Examining the Mediating Roles of Implantable Cardioverter Defibrillator-Related Concerns and Perceived Control.

100 Association of alprazolam with major cardiovascular events in patients with hypertension.

101 A Novel Approach to High-Performance Aliovalent-Substituted Catalysts-2D Bimetallic MOF-Derived CeCuO Microsheets.

Keyword Connections

Journals

Research Groups

Bibliographies